Results 211 to 220 of about 106,112 (301)

Effects of Siltuximab Versus Corticosteroids in Preventing COVID−19 Pneumonia Disease Progression: Multicentre, Open‐Label, Randomized Clinical Trial

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT In 2020, COVID‐19 caused a global health crisis, prompting research efforts and accelerating drug development. As part of this response, we conducted a phase 2b, multicentre, open‐label, randomized (1:1) clinical trial to compare the effects of siltuximab versus corticosteroids on disease progression in hospitalized adults with COVID‐19 ...
Lorna Leal, María del Puerto Bernoy González, Clara Castán, Fernanda Meira, Gerard Dueñas, Judit Pich, Marta Hernández‐Meneses, Verónica Rico, Nicole García‐Pouton, Daiana Agüero, Elisa de Lazzari, Adrià Tomé, Sabina Herrera, José Muñóz, Alex Almuedo, Sergio Prieto‐González, Pedro Castro, Maria Angeles Marcos, Montse Tuset, Roger Paredes, Cristina Carbonell, David Dalmau, José Antonio Martínez, Alex Soriano, Felipe García, SILCOR study group, A. Moreno, M. Solá, A. Ugarte, A. Gonzalez‐Cordón, M. Laguno, J. Rojas, B. Torres, J. Ambrosioni, L. Morata, C. García‐Vidal, C. Cardozo, M. Bodro, M. Chumbita, L. de la Mora, A. Inciarte, P. Puerta‐Alcalde, A. del Rio, S. Fernandez, A. Tellez, D. Camprubi, M. T. de Alba, M. Fernandez, E. Ferrer, B. Grau, H. Marti, M. Muelas, M. J. Pinazo, N. Rodriguez, A. Aldea, J. Calvo, A. Capdevila, I. Carbonell, A. Foncillas, M. Feliu, C. Gabara, I. Grafia, A. Ladino, A. López‐Soto, A. Matas, J. Marco‐Hernández, P. Moreno, J. Naval, J. Padrosa, M. Pellicé, J. Ribot, O. Rodríguez‐Núnez, F. Seguí, H. Ventosa, C. Zamora‐Martínez, M. Alvarez, E. Rubio, A. Vergara   +77 more
wiley   +1 more source

Early use of tocilizumab in solid organ transplant recipients with COVID‐19: A retrospective cohort study in Saudi Arabia

, 2022
Amani H. Yamani, Basem Alraddadi, Reem S. Almaghrabi, Afnan A. Amer, Fatimah S. Mehdawi, Mohammed A. Al-Hamzi, Meshari S. Aldajani, Majda Alattas, Aiman M. Elsaed Ramadan, Ghassan Wali, Abeer N. Alshukairi, Abbas Al Mutair   +11 more
openalex   +1 more source

Effectiveness and safety of tocilizumab in refractory noninfectious uveitis: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Kang H, Wu X, Xu H, Huang Y, Zhang M.
europepmc   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

Longitudinal Comparison of Calprotectin and C-Reactive Protein in Rheumatoid Arthritis: Real-World Evidence Across Three Targeted Therapies. [PDF]

Diagnostics (Basel)
Fassio A, Galvagni I, Sartoris S, Cassandrini DA, Aldegheri F, Rossini M, Pollastri F, Adami G, Gatti D, Somma R, Appoloni M, Carletto A, Bronte V, Arcolaci A.   +13 more
europepmc   +1 more source

Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions [PDF]

, 2012
Atsushi Ogata, Toshio Tanaka
openalex   +1 more source

A Case of Steroid-Dependent Immune Checkpoint Inhibitor Pneumonitis Treated With Subcutaneous Tocilizumab. [PDF]

Respirol Case Rep
Chang N, Meara A, Ho K.
europepmc   +1 more source

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study. [PDF]

Am J Health Syst Pharm
Malone DC, Seheult R, Brixner D, Oderda G, Burnett BP, Biskupiak J.   +5 more
europepmc   +1 more source

1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China

European Journal of Neurology, Volume 33, Issue 2, February 2026.
In this prospective cohort of 282 patients with myasthenic crisis (MC) episodes, all‐cause mortality was 15.16%. Among 247 patients who have completed 1‐year follow‐up, 79.76% achieved favorable outcomes with significant improvement in the MG‐activities of daily living (MG‐ADL) score.
Xiao Huan, Ran Chen, Lei Jin, Yuan Wang, Yafang Xu, Lei Yang, Caihua Xi, Jianming Zheng, Lijun Luo, Song Yang, Jianquan Shi, Yanping Liu, Zhe Ruan, Wanlong Wu, Wei Li, Yaoxian Yue, Yarong Li, Wenji Jia, Huahua Zhong, Chong Yan, Jie Song, Jianying Xi, Song Tan, Qilong Jiang, Zhangyu Zou, Chongbo Zhao, Sushan Luo, on behalf of the Chinese Myasthenia Gravis Collaborating Group (CMGCG), Yuzhou Guan, Yuwei Da, Huan Yang, Ting Chang, Yuge Wang, Bitao Bu, Hongyu Zhou, Chunsheng Yang, Hua Zhang, Hui Deng, Ruisheng Duan   +38 more
wiley   +1 more source